INTERVENTIONAL

Multi-institutional analysis of outcomes for thermosphere microwave ablation treatment of colorectal liver metastases: the SMAC study

Francesco De Cobelli1,2,3 · Marco Calandri4,5 · Angelo Della Corte1,2,3 · Roberta Sirovich6 · Carlo Gazzera7 · Paolo Della Vigna8 · Guido Bonomo8 · Gianluca Maria Varano8 · Daniele Maiettini8 · Giovanni Mauri8,9 · Nicola Camisassi8 · Stephanie Steidler1,2 · Francesca Ratti10 · Simone Gusmini1 · Monica Ronzoni11 · Luca Aldrighetti3,10 · Bruno C. Odisio12 · Patrizia Racca13 · Paolo Fonio7,14 · Andrea Veltri4,5 · Franco Orsi8

Received: 31 May 2021 / Revised: 29 October 2021 / Accepted: 17 November 2021 / Published online: 29 January 2022
© The Author(s) 2022

Abstract

Objectives Oligometastatic colorectal cancer benefits of locoregional treatments but data concerning microwave ablation (MWA) are limited and interactions with systemic therapy are still debated. The aim of this study is to evaluate safety and effectiveness of Thermosphere™ MWA (T-MWA) of colorectal liver metastases (CLM) and factors affecting local tumor progression-free survival (LTPFS).

Methods In this multi-institutional retrospective study (January 2015–September 2019), patients who underwent T-MWA for CLM were enrolled. Complications according to SIR classification were collected, primary efficacy and LTP were calculated. Analyzed variables included CLM size at diagnosis and at ablation, CLM number, ablation margins, intra-segment progression, chemotherapy before ablation (CBA), variations in size ($\Delta S_{\text{DIA-ABL}}$), and velocity of size variation ($V_{\text{DIA-ABL}}$) between CLM diagnosis and ablation. Uni/multivariate analyses were performed using mixed effects Cox model to account for the hierarchical structure of data, patient/lesions.

Results One hundred thirty-two patients with 213 CLM were evaluated. Complications were reported in 6/150 procedures (4%); no biliary complications occurred. Primary efficacy was achieved in 204/213 CLM (95.7%). LTP occurred in 58/204 CLM (28.4%). Six-, twelve-, and eighteen-month LTPFS were 88.2%, 75.8%, and 69.9%, respectively. At multivariate analysis, CLM size at ablation ($p = 0.00045$), CLM number ($p = 0.046$), ablation margin < 5 mm ($p = 0.0035$), and intra-segment progression ($p < 0.0001$) were statistically significant for LTPFS. $\Delta S_{\text{DIA-ABL}}$ ($p = 0.63$) and $V_{\text{DIA-ABL}}$ ($p = 0.38$) did not affect LTPFS. Ablation margins in the chemo-naïve group were larger than those in the CBA group ($p < 0.0001$).

Francesco De Cobelli and Marco Calandri contributed equally to this work.

Marco Calandri
marco.calandri@unito.it

1 Department of Radiology, IRCCS San Raffaele Hospital, Milan, Italy
2 Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy
3 School of Medicine, Vita-Salute San Raffaele University, Milan, Italy
4 Department of Oncology, University of Torino, Turin, Italy
5 Interventional Radiology Unit, AOU San Luigi Gonzaga, Orbassano, Turin, Italy
6 Department of Mathematics “Giuseppe Peano”, University of Torino, Turin, Italy
7 Radiology Unit, AOU Città Della Salute E Della Scienza, Turin, Italy
8 Divisione Di Radiologia Interventistica, Istituto Europeo Di Oncologia, Istituto Di Ricovero E Cura a Carattere Scientifico (IRCCS), Milan, Italy
9 Dipartimento Di Oncologia Ed Emato-Oncologia, Università Degli Studi Di Milano, Milan, Italy
10 Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy
11 Unit of Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
12 The University of Texas, Department of Interventional Radiology, MD Anderson Cancer Center, Houston, TX, USA
13 ColoRectal Cancer Unit, Department of Oncology, AOU Città Della Salute E Della Scienza, Turin, Italy
14 Department of Surgical Sciences, University of Torino, Turin, Italy
Conclusion  T-MWA is a safe and effective technology with adequate LTPFS rates. Intra-segment progression is significantly linked to LTPFS. CBA does not affect LTPFS. Anticipating ablation before chemotherapy may take the advantages of adequate tumor size with correct ablation margin planning.

Key Points
- Thermosphere™-Microwave ablation is a safe and effective treatment for colorectal liver metastases with no registered biliary complications in more than 200 ablations.
- Metastases size at time of ablation, intra-segment progression, and minimal ablation margin < 5 mm were found statistically significant for local tumor progression-free survival.
- Chemotherapy before ablation modifies kinetics growth of the lesions but deteriorates ablation margins and does not significantly impact local tumor progression-free survival.

Keywords  Colorectal neoplasms · Ablation · Microwaves

Abbreviations
CBA  Chemotherapy before ablation
CLM  Colorectal liver metastases
CT  Computed tomography
LRT  Locoregional therapies
LTP  Local tumor progression
LTPFS  Local tumor progression-free survival
MRI  Magnetic resonance imaging
MWA  Microwave ablation
OS  Overall survival
RFA  Radiofrequency ablation
SBRT  Stereotactic body radiation therapy
T-MWA  Thermosphere microwave ablation
VDIA-ABL  Velocity of size change from diagnosis to ablation
ΔSDIA-ABL  Degree of size change from diagnosis to ablation

Introduction
Colorectal cancer is the third most common tumor in both men and women. About a third of patients with a diagnosis of colorectal cancer during their lifetime will develop liver metastases (CLM) [1, 2] which represent a major prognostic determinant [3, 4].

In this field of treatment, specifically in the oligometastatic setting, locoregional treatments (LRTs) have recently been endorsed by NCCN [5] and ESMO guidelines [6] in the management of CLM. In the ESMO consensus guidelines, liver surgery, stereotactic body radiation therapy (SBRT), radiofrequency (RFA), microwave ablation (MWA), and trans-arterial therapies are all included in the LRTs toolbox, where physicians can select the best treatment for the right patient during tumor boards [6]. However, therapeutic indication varies according to the local expertise also due to the non-homogeneous scientific evidence regarding the different LRTs. Furthermore, data concerning interaction of interventional treatments and systemic therapies are still limited [7, 8] or lacking.

Among image-guided ablation techniques, RFA is by far the most extensively investigated with milestone papers [9, 10]. MWA has been more recently proposed as an alternative ablation technique and is gaining popularity among interventional radiologists [11] as it represents some advantages over RFA, such as reduced “heat-sink” effect (lower heat dissipation in a vessel’s proximity) and larger ablation zones over a shorter period of time. The poor level of predictability of the ablation zone however is one of the well-known limitations of MWA probes. Thermosphere™ technology is a relatively recent advance of MWA whereby a combination of thermal control, field control, and wavelength control leads to the formation of a reliable spherical ablation zone [12]. This technique is currently investigated in the ongoing European prospective registry (CIEMAR-NCT03775980) and has already shown the potential of improving results of MWA in different clinical settings [13–15].

As recently highlighted [16], despite acknowledgments from the oncological guidelines and significant technical advancements, a relatively small number of studies have investigated the efficacy of MWA in the CLM setting and, specifically, no pertinent information is present about MWA with Thermosphere™ technology only (T-MWA). Furthermore, data are lacking about the interactions between ablative treatments and timing of concomitant systemic therapies and the growth kinetics of metastatic disease.

We therefore aimed at evaluating safety and effectiveness of T-MWA of CLM and factors affecting local tumor progression-free survival (LTPFS).

Methods

Study design
The study was approved by the IRBs of the three institutions (San Raffaele University Hospital, Milan (institution A); University of Torino (institution B); and Istituto Europeo di Oncologia, Milan (institution C)) in full respect of the
Declarion of Helsinki and its later amendments. Informed consent was waived for this retrospective analysis.

Liver ablation registries of the three institutions were retrospectively evaluated and updated by review of the electronic medical records to select consecutive patients who underwent image-guided microwave ablation with Thermosphere™ technology for the treatment of CLM from January 2015 to September 2019.

**Ablation eligibility criteria, patient selection, and technique**

Patient eligibility for ablation was discussed at each institutions’ multidisciplinary tumor boards. Patients underwent image-guided ablation if not amenable to surgery, in case of refusal to or in combination with surgery. In all three institutions, CLM were ablated if they did not exceed 5 cm in size and 5 lesions in number [17]. No oncological criteria were used for ablation eligibility.

Patients had to fulfill the following inclusion criteria: clinical and imaging evidence of CLM (radiological diagnosis of metastases on pre-operative dynamic contrast-enhanced imaging with a liver-specific acquisition protocol); availability of CT imaging at diagnosis and/or before ablation within 1 month from the procedure.

Percutaneous approach was free-hand ultrasound-guided or CT-guided (institutions A, B, and C) according to ultrasound conspicuity and local expertise, either under deep sedation (institutions A and B) or general anesthesia (institution C). Laparotomic and laparoscopic procedures (institutions A and C) were performed in the operating room with free-hand ultrasound guidance under general anesthesia.

All ablations were performed by experienced IRs in all centers using a 2450-MHz/100-W Microwave Emprint™ ablation system with Thermosphere™ technology (Medtronic).

Ablation protocol (power and time) was tailored to tumor size according to the manufacturer’s instructions (Ablation Zone Charts. R0065469, Instructions for Use, Emprint™).

**Collected data**

For each patient, collected data were as follows: gender, age, TNM at diagnosis, mutational status (including KRAS and NRAS), location of primary CRC, clinical risk score [18], history of previous CLM resection or LRTs, chemotherapy before and after ablation, CLM number, and all the available imaging (pre- and post-procedure).

For each CLM, collected data included the following: size (at diagnosis and at ablation), intrahepatic location, time of appearance on imaging (synchronous/metachronous), amount of delivered energy over tumor size \((W \times S/mm)\).

CLM diameter at diagnosis and at the time of procedure was expressed both as a continuous variable and as a categorical entity (with cutoff values at 10, 15, 20, 25, 30, 35 mm). Available cross-sectional imaging from diagnosis to the time of ablation was reviewed in order to identify changes in size of the target lesions. Based on these data, information was acquired regarding degree of tumor size change from diagnosis to ablation \((\Delta S_{\text{DIA-ABL}})) as well as velocity of size variation \((S_{\text{DIA-ABL}}))

**Technique efficacy, tumor recurrence, and follow-up**

Standardized terminology and reporting criteria for tumor ablation were used to determine ablation endpoints according to Ahmed et al. [19]. Complications were classified according to the SIR classification [20].

Technical success was assessed immediately after the procedure, by means of contrast-enhanced CT (for CT-guided procedures) or ultrasound evaluation (for US-guided procedures).

Technique efficacy was defined as absence of pathological enhancement at the ablation zone (residual tumor) on imaging (CT or MRI) at 1 month after ablation [21].

Minimal ablation margin evaluation on the three orthogonal planes was performed as previously described by Wang et al. [22] using the first cross-sectional contrast-enhanced imaging study following ablation.

The minimal ablation margin achieved in all three-dimensional axes was used to categorize the ablated CLM as having \(\leq 5\) mm or \(> 5\) mm and \(\leq 10\) mm or \(> 10\) mm minimal ablation margin.

Institutional follow-up for all three institutions included CT/MRI using a liver-specific acquisition protocol 1 month after the procedure, then every 3 months for the first year and every 6 months thereafter.

Local tumor progression (LTP) was defined as appearance of foci of vital disease at the edge of the ablation area at any of the follow-up time points [19]. Intra-segment progression was defined as appearance of metastases within the same segment as the ablation area, at a minimum distance of \(> 1\) cm from the ablated index lesion.

Intrahepatic progression was defined as appearance of metastases in any liver site outside of the ablation area. Data regarding overall survival (OS) were also recorded.

**Statistical analysis**

Patient characteristics were described using standard descriptive statistics. Frequencies presented as percentages were used to express categorical values; median values with respective interquartile ranges were used for continuous variables.
Statistical analysis was performed with the open-source software R studio (R Foundation for Statistical Computing, www.r-project.org) by a qualified academic biostatistician (R.S.). Survival curves were generated with the Kaplan–Meier method and evaluated with the log-rank test. Univariate and multivariate analyses were performed using mixed effects Cox models, with random intercept per group in order to reduce to potential bias of multiple nodules per patient. Analysis was considered statistically significant if \( p < 0.05 \).

**Results**

**Patient and CLM characteristics**

During the study period, a total of 228 consecutive patients who underwent CLM ablation were identified. Patients with follow-up < 6 months \((n = 42)\), lack of available cross-sectional imaging at diagnosis and/or the first CT control \((n = 31)\), and CLM ablation performed with non-Thermosphere\textsuperscript{TM} technology \((n = 23)\) were excluded from analysis (Fig. 1).

After exclusions, a total of 132 patients (mean age 65.1 years [range 39–86]) who were deemed not to be surgical candidates \((n = 82)\), refused surgery \((n = 2)\), or underwent combined surgical/ablative approach \((n = 48)\) were included in the analysis. Of these patients, 70 underwent chemotherapy after lesion identification prior to ablation (53%).

A total of 213 CLM were ablated in 150 procedures and included in the analysis (median size 1.4 cm [range 0.3–3.7]); 80 lesions were synchronous and 124 were metachronous.

The median follow-up period was 19 months (range 6–55 months). Patient and tumor characteristics at baseline are summarized in Table 1.

Comparison between institutions A, B, and C revealed homogeneity in most of the analyzed data such as gender, presence of extrahepatic disease at time of ablation, number of ablations in a single session, post-ablation chemotherapy, KRAS and NRAS mutations, localization and nodal status of primary tumor, CEA level at time of...
The evaluation regarding similarities and differences among institutions is available as supplementary material (Tables S1 and S2).

### Table 1: Baseline characteristics

| Characteristic                  | Value |
|--------------------------------|-------|
| **Patients (N=132)**           |       |
| Gender                         |       |
| Male                           | 86 (65.2%) |
| Female                         | 46 (34.8%) |
| Age (years) > 70               | 45 (34.1%) |
| > 5 Lesions                    | 26 (19.7%) |
| EHD at time of ablation        | 34 (25.8%) |
| Indication for ablation        | NRAS mut 4 (3%) |
| Non-surgical candidate         | NRAS wt 98 (74.2%) |
| Surgery refusal                | 2 (1.5%) |
| Combined approach              | 48 (36.4%) |
| Technical approach             |       |
| Percutaneous                   | 76 (57.6%) |
| Laparoscopic                   | 17 (12.9%) |
| Laparotomic                    | 38 (28.8%) |
| Imaging guidance               |       |
| Ultrasound                     | 95 (72.5%) |
| CT                             | 36 (27.3%) |
| Lesions ablated per session    |       |
| Single                         | 88 (66.7%) |
| Multiple                       | 44 (33.3%) |
| **CLM (N=204)**                |       |
| Size at ablation (mm)          | 15.4 ± 8 (3–37) |
| Size at CSI                    | 14.8 ± 8.2 (3–46) |
| Largest lesion size at any time| 18.4 ± 9.5 (3–47) |
| Previous LRT                   | 41 (19.2%) |
| TARE                           | 3 (1.4%) |
| RFA                            | 28 (13.1%) |
| Resection                      | 10 (4.7%) |
| Location of primary tumor      |       |
| Male                           | Cecum 8 (6.1%) |
| Female                         | Ascending colon 19 (14.4%) |
| Age (years) > 70               | Transverse colon 3 (2.3%) |
| > 5 Lesions                    | Descending colon 26 (19.7%) |
| EHD at time of ablation        | Sigmoid colon 35 (26.5%) |
| Indication for ablation        | Rectum 40 (30.3%) |
| Non-surgical candidate         | Missing 1 (0.8%) |
| Surgery refusal                | Nodal status of primary 0 35 (26.5%) |
| Combined approach              |       |
| Technical approach             |       |
| Percutaneous                   |       |
| Laparoscopic                   |       |
| Laparotomic                    |       |
| Imaging guidance               |       |
| Ultrasound                     |       |
| CT                             |       |
| Lesions ablated per session    |       |
| Single                         |       |
| Multiple                       |       |
| Size at ablation (mm)          |       |
| Size at CSI                    |       |
| Largest lesion size at any time|       |
| Previous LRT                   |       |
| TARE                           |       |
| RFA                            |       |
| Resection                      |       |
| Location of primary tumor      |       |

**Key Abbreviations:**

- **EHD:** extrahepatic disease
- **CT:** computed tomography
- **CEA:** carcinoembryonic antigen
- **CRC:** colorectal cancer
- **CLM:** colorectal liver metastases
- **LRT:** locoregional treatment
- **TARE:** trans-arterial radioembolization
- **RFA:** radiofrequency ablation
- **RECIST:** Response Evaluation Criteria in Solid Tumors
- **PD:** progressive disease
- **SD:** stable disease
- **PR:** partial response

- **NRAS:** nonsense mutation
- **KRAS:** Kras gene
- **CEA at diagnosis of primary tumor:** 81.8 ± 933.7 (1.3–7288.6)0 35 (26.5%)
- **CEA at time of ablation:** 7.7 ± 24.2 (0.8–118.5) 1 59 (44.7%)
- **Clinical risk score:** 1 59 (44.7%)
- **Grade of primary tumor:** G1 4 (3%) G2 82 (31.8%) G3 23 (17.4%) Missing 23 (17.4%)
- **Nodal status of primary tumor:** 0 35 (26.5%)
- **Previous hepatic resection:** 38 (28.8%)
- **Post-ablation chemotherapy:** 61 (46.2%)
- **Synchronous:** 39 (39%)
- **Metachronous:** 130 (61%)
- **Time from lesion discovery to ablation:** 160.6 ± 158.8 (5–779)
- **Response to pre-ablation chemotherapy (RECIST1.1):** 406.7 ± 382.5 (5–1464)
- **Time from last chemotherapy cycle to ablation:** 68.17 ± 60.55 (0–381) PD 28 (29.5%)
- **Time from last hepatic resection to ablation:** 406.7 ± 382.5 (5–1464)
- **Response to pre-ablation chemotherapy (RECIST1.1):** 406.7 ± 382.5 (5–1464)
- **Time from last chemotherapy cycle to ablation:** 68.17 ± 60.55 (0–381) PD 28 (29.5%)
Table 2 LTPFS mixed effects Cox model. LTPFS, local tumor progression-free survival; HR, hazard ratio; CEA, carcinoembryonic antigen; CLM, colorectal liver metastases; LRT, locoregional therapy; RECIST, Response Evaluation Criteria in Solid Tumors; PD, progressive disease; SD, stable disease; PR, partial response

| Variable                                      | Univariate |             | Multiivariate |             |
|-----------------------------------------------|------------|-------------|---------------|-------------|
|                                               | Coefficient| HR          | Standard error| p           |
| Gender                                        | 0.48       | 1.62        | 0.37          | 0.2         |
| Age > 70                                      | 0.23       | 1.26        | 0.35          | 0.52        |
| Center (baseline B)                           |            |             |               |             |
| A                                             | −0.41      | 0.66        | 0.49          | 0.41        |
| C                                             | 0.09       | 1.1         | 0.47          | 0.85        |
| Extrahepatic disease at time of ablation      | −0.42      | 0.65        | 0.43          | 0.33        |
| Percutaneous (baseline)                       |            |             |               |             |
| Laparoscopic                                  | −0.5       | 0.60        | 0.49          | 0.3         |
| Open                                          | −0.75      | 0.47        | 0.41          | 0.07        |
| Imaging guidance                              | −0.44      | 0.65        | 0.36          | 0.23        |
| Number of lesions ablated per session         | 0.03       | 1.03        | 0.15          | 0.84        |
| >1 lesion ablated                             | 0.48       | 1.62        | 0.34          | 0.16        |
| >3 lesions ablated                            | 0.89       | 2.44        | 0.47          | 0.056       |
| Hepatic resection (baseline none)             |            |             |               |             |
| Pre-ablation                                  | 0.63       | 1.88        | 0.39          | 0.11        |
| Post-ablation                                 | −0.09      | 0.91        | 0.55          | 0.87        |
| Time from hepatic resection to ablation       | 0.0014     | 1.001       | 0.0012        | 0.23        |
| Post-ablation chemotherapy                    | −0.39      | 0.67        | 0.35          | 0.26        |
| AllRas mutation                               | −0.34      | 0.71        | 0.41          | 0.4         |
| KRAS                                          | −0.15      | 0.86        | 0.42          | 0.73        |
| NRAS                                          | −21.26     | 0           | 3.4768        | 1           |
| CEA at diagnosis of primary tumor             | −0.00023   | 1           | 0.00047       | 0.63        |
| CEA at diagnosis of primary tumor > 200 ng/mL | 0.06       | 1.06        | 0.78          | 0.94        |
| CEA at time of ablation                       | −0.009     | 0.99        | 0.012         | 0.45        |
| Clinical risk score                           |            |             |               |             |
| 1                                             | −0.69      | 0.5         | 0.96          | 0.47        |
| 2                                             | −0.72      | 0.49        | 0.8           | 0.4         |
| 3                                             | −0.89      | 0.41        | 0.82          | 0.27        |
| 4                                             | −0.08      | 0.92        | 0.92          | 0.93        |
| 5                                             | −18.8      | 0           | 15.988        | 1           |
| Location of primary tumor (baseline cecum)    |            |             |               |             |
| Ascending                                     | 0.75       | 2.12        | 0.76          | 0.32        |
| Transverse                                    | −20.02     | 0           | 24.134        | 1           |
| Descending                                    | 0.34       | 1.4         | 0.72          | 0.64        |
| Sigma                                         | 0.2        | 1.22        | 0.71          | 0.78        |
| Rectum                                       | −0.25      | 0.77        | 0.72          | 0.72        |
| Nodal status of primary tumor                 |            |             |               |             |
| 1                                             | −0.14      | 0.87        | 0.5           | 0.78        |
| 1a                                            | −1.34      | 0.26        | 0.8           | 0.093       |
| 1b                                            | −0.04      | 0.96        | 0.54          | 0.94        |
| 1c                                            | 0.99       | 2.69        | 0.7           | 0.16        |
| 2                                             | 0.35       | 1.42        | 0.65          | 0.59        |
| 2a                                            | −0.13      | 0.88        | 0.55          | 0.81        |
| 2b                                            | −0.12      | 0.89        | 0.8           | 0.89        |
| Metastatic disease at diagnosis               | −0.15      | 0.86        | 0.36          | 0.67        |
| CLM size at ablation                          | 0.08       | 1.08        | 0.021         | 0.0001      |
| CLM size at diagnosis                         | 0.056      | 1.06        | 0.017         | 0.0008      |
Local, hepatic, and patient outcomes

Primary efficacy was observed in 204/213 nodules (95.7%). Of the 9 cases with incomplete ablation, one underwent repeated ablation and 4 refused further local treatments and underwent chemotherapy; one case had a multifocal relapse observed at 1-month follow-up and was switched to chemotherapy; in the remaining 3 cases, surgical resection was performed on the incompletely ablated nodule.

No fatal events occurred after ablation. Complications were observed in 6/150 procedures (4%), of which three were classified as minor (two non-bleeding hematomas which did not require further treatment and one case with a collection which required antibiotic therapy) and 3 were classified as major (three cases of pleural effusion managed with drainage placement).

LTP was observed in 58/204 CLM during the follow-up period (28.4%). Six-, twelve-, and eighteen-month LTPFS were 88.2%, 75.8%, and 69.9%, respectively. Twelve out of 58 LTPs underwent re-ablation (20.7%), whereas 31 (53.4%) were scheduled to receive chemotherapy due to multifocal liver progression, 5 (8.6%) underwent surgical resection, and 10 (17.2%) refused further treatments.

Intrahepatic progression was observed in 79/132 patients during the follow-up period (59.8%). Six, twelve, and eighteen months, intrahepatic progression-free survival rates were 65.8%, 56%, and 36.8%, respectively.

Cancer-related deaths occurred in 14/132 patients during the follow-up period (10.6%). Twelve- and twenty-four-month OS were 98.3% and 89.9%, respectively.

Univariate and multivariate analyses

At univariate analysis (Table 2), risk factors for occurrence of LTP were CLM size at ablation (HR = 1.08, \( p < 0.0001 \)), CLM size at ablation > 2 cm (HR = 2.55, \( p = 0.00157 \)), CLM size at CSI diagnosis (HR = 1.06, \( p = 0.0008 \)), largest CLM size at any time point before ablation (HR = 1.07, \( p < 0.0001 \)), and intra-segment progression (HR = 3.05, \( p < 0.0001 \)). Margins ≥ 5 mm (HR = 0.28, \( p = 0.0025 \)) and margins > 10 mm (HR = 0.24, \( p = 0.0014 \)) were both protective factors for LTP.

At the multivariate analysis (Table 2), a balanced model for LTPFS including CLM number (\( p = 0.046 \)), size at ablation (\( p = 0.00045 \)), minimal ablation margin ≥ 5 mm (\( p = 0.0035 \)), and intra-segment progression (\( p < 0.0001 \)) was created.

Lesion size and growth kinetics analysis

CLM size at diagnosis on cross-sectional imaging was 14.8 ± 8 mm (3–46 mm); CLM size at time of ablation was 15.4 ± 8 mm (3–37 mm). Mean time from detection to ablation was 160.6 ± 158.8 days (0–779).
Table 3 LTPFS univariate mixed effects Cox model on size. LTPFS, local tumor progression-free survival; HR, hazard ratio; ΔSDIA-ABL, size change from diagnosis to ablation; VDIA-ABL, velocity of size change from diagnosis to ablation.

| Variable                      | Coefficient | HR   | Standard Error | p       |
|-------------------------------|-------------|------|----------------|---------|
| Size at ablation              | 0.08        | 1.08 | 0.02           | 0.0001  |
| Size at ablation > 10 mm      | 1.36        | 3.88 | 0.39           | 0.0005  |
| Size at ablation > 15 mm      | 0.99        | 2.68 | 0.33           | 0.003   |
| Size at ablation > 20 mm      | 1.06        | 2.89 | 0.34           | 0.002   |
| Size at ablation > 25 mm      | 1.29        | 3.65 | 0.4            | 0.0014  |
| Size at ablation > 30 mm      | 0.75        | 2.12 | 1.1            | 0.5     |
| Size at ablation > 35 mm      | −19.11      | 0    | 23.030         | 1       |
| Size at diagnosis             | 0.06        | 1.06 | 0.02           | 0.0008  |
| Size at diagnosis > 10 mm     | 1.52        | 4.58 | 0.4            | 0.00016 |
| Size at diagnosis > 15 mm     | 0.95        | 2.58 | 0.3            | 0.0034  |
| Size at diagnosis > 20 mm     | 0.5         | 1.65 | 0.4            | 0.22    |
| Size at diagnosis > 25 mm     | 0.83        | 2.29 | 0.46           | 0.07    |
| Size at diagnosis > 30 mm     | 1.19        | 3.29 | 0.52           | 0.022   |
| Size at diagnosis > 35 mm     | 1.56        | 4.74 | 0.65           | 0.017   |
| ΔSDIA-ABL > 0 mm              | 0.06        | 1.01 | 0.02           | 0.78    |
| ΔVIA-ABL > 0 mm               | −0.043      | 0.96 | 0.32           | 0.89    |
| ΔVIA-ABL > 0 mm/day           | −0.21       | 0.8  | 0.3            | 0.53    |

Bold values are statistically significant (p < 0.05)

CLM size both at time of ablation and at time of diagnosis was a statistically significant predictor of LTP, analyzed as a continuous variable as well as using different thresholds (HR varying from 1.08 to 4.74, p varying from 0.0001 to 0.022, see Table 3).

Mean ΔSDIA-ABL was 0.8 ± 8.8 mm (−31/ +22); mean VDIA-ABL was 0.06 ± 0.2 mm/day (−0.16/ +2.29). No association was seen between LTPFS and ΔSDIA-ABL (p = 0.78) or VDIA-ABL (p = 0.3).

Chemotherapy before ablation (CBA) was administered in one hundred twelve out of 204 CLM (70 patients). Regimens administered included the following: n = 5 capecitabine; n = 2 capecitabine + bevacizumab; n = 2 folfox, n = 11 folfox + bevacizumab; n = 4 folfox + cetuximab, n = 9 folfox, n = 14 folfox + bevacizumab, n = 10 xelox; n = 9 folfox + panitumumab, n = 4 folfoxiri + bevacizumab. Time elapsed between detection and ablation was longer in CLM undergoing CBA (240 ± 170.8 days vs 63 ± 62 days, p < 0.001). Differences and similarities between the CBA and chemo-naïve groups are summarized in Table 4.

LTP was observed in 36/112 CLM undergoing CBA (32.1%) and 22/92 chemo-naïve CLM (23.9%, p = 0.21). At univariate analysis, CBA was not associated with LTPFS (p = 0.22).

At time of diagnosis, lesion size was slightly higher in CLM receiving CBA (16.8 ± 6 mm vs 13 ± 6 mm, p = 0.015), whereas at time of ablation, size was higher in chemo-naïve CLM (17.5 ± 8 vs 13.4 ± 7, p < 0.001). No statistical difference was observed between size at diagnosis in the CBA group and size at ablation in chemo-naïve CLM (chemo-treated 16.8 ± 9 mm; chemo-naïve 17.5 ± 8, p = 0.45). Size distribution at diagnosis and at ablation according to subgroups based on history of CBA is reported in Fig. 2. Margins in the chemo-naïve groups were significantly larger than those in the CBA group (margins < 5 mm groups, p = 0.035; margins > 10 mm groups, p < 0.0001).

ΔSDIA-ABL and VDIA-ABL were significantly higher in CLM not undergoing CBA (ΔSDIA-ABL: 4.8 ± 5.4 mm vs −2.9 ± 9.7 mm, p < 0.001; VDIA-ABL: 0.13 ± 0.28 vs −0.007 ± 0.06, p < 0.001). Distribution of ΔSDIA-ABL and VDIA-ABL is shown in Fig. 3 and depicted for each single lesion in Fig. 4.

Discussion

Our multicenter study gives pertinent information regarding T-MWA and analyzes the lesion size in a dynamic approach, investigating the kinetics growth before ablation and factors that can modify it.

Table 4 CLM characteristics according to subgroups based on pre-ablation chemotherapy. CLM, colorectal liver metastases; CBA, chemotherapy before ablation; CSI, cross-sectional imaging.

| Variables                      | CBA (N = 112) | Chemo-naive (N = 92) | p       |
|-------------------------------|---------------|----------------------|---------|
| Size at ablation (mm)         | 13.4 ± 7 (3–35)| 17.5 ± 8 (5–37)     | <0.0001 |
| Size at CSI                   | 16.8 ± 9 (3–46)| 13 ± 6 (4–30)       | 0.015   |
| Amount of delivered energy (W×s/mm) | 2253.56 ± 1340.25 (545–10,000) | 2179.5 ± 1148 (700–7125) | 0.6     |
| Subcapsular location          | 24 (21.4%)    | 28 (30.4%)           | 0.15    |
| Proximity to vessels > 3 mm   | 41 (36.6%)    | 34 (37%)             | 0.53    |
| Margin < 5 mm                 | 43 (38.4%)    | 23 (25%)             | 0.035   |
| Margin 5–10 mm                | 46 (41%)      | 27 (29.3%)           | 0.82    |
| Margin > 10 mm                | 23 (20.6%)    | 42 (45.6%)           | <0.0001 |
| Local tumor progression       | 36 (32.14%)   | 22 (23.9%)           | 0.2     |

Bold values are statistically significant (p < 0.05)
Briefly, our findings highlight that:

- T-MWA is a safe technique (2% of major complications, with no biliary complications) with satisfying LTPFS rates at 12 months (75.8%);
- Multivariate analysis with Cox regression confirms lesion size, minimum margins size, and number of hepatic lesions <3 as factors influencing outcome and unveils a relationship between intra-segment progression and LTPFS;
- Lesion size clearly impacts outcome, also when measured at time of diagnosis ($p=0.000237$);
- Chemotherapy before ablation modifies growth kinetics (both $\Delta S_{\text{DIA-ABL}}$ and $V_{\text{DIA-ABL}}$) but deteriorates ablation margin width and does not significantly impact LTPFS ($p=0.37$).

Literature concerning microwave ablation of colorectal liver metastases or factors impacting outcome is relatively few if compared with other therapies present in the ESMO toolbox (in primis, RFA, or surgery). T-MWA, introduced in the clinical practice in 2015, has gained acceptance as a valid tool for treatment and is recently being investigated in the first European prospective registry (CIEMAR) whose results are expected in 2025. Moreover, a phase III single-blind prospective randomized controlled trial (the COLLISION trial [23]) is ongoing with the objective to prove non-inferiority of MWA compared to hepatic resection in patients with at least one resectable and ablatable CLM and no extrahepatic disease. Thus, our paper represents the first multicenter retrospective analysis of results achieved in the clinical practice with the application of T-MWA in the treatment of CLM.

According to our results, T-MWA is a safe technology with LTPFS rates of 88.2%, 75.8%, and 69.9% at 6, 12, and 18 months. These results are comparable with recently published data in a historic single center RFA cohort [9] and comparable with other previously published cohorts [24].

Concerning adverse events, major complications (listed according to SIR classification) occurred in 2% of the procedures, with no related deaths. This is consistent (even inferior) with other MWA series, such as the 2.6% according to Liang et al. [25]. Furthermore, although the site of the lesions was not classified as peri-hilar or not in our study, no biliary complications were accounted for after T-MWA procedures; this is a relevant finding, especially if compared with other literature reports concerning MWA technologies with higher numbers of reported biliary ducts injuries [26].

Multivariate analysis confirms lesion size, minimum margin size, and the number of hepatic lesions as factors affecting LTPFS. This is consistent with the published data concerning the RFA procedures [22, 24, 27–29], once more highlighting the prominent role of accurate patient selection and the need of an effective interventional technique.

To the best of our knowledge, for the first time, intra-segment progression was evaluated in the analysis and found statistically significant in a multivariate model (while hepatic progression outside the ablated lesion was not). Intra-segment progression was defined as the appearance of tumor foci in the segment of the ablated lesion apart from

---

Fig. 2. Lesion size at time of diagnosis and at time of ablation. The population was studied according to chemotreated lesions or chemo-naïve lesions. CBA, chemotherapy before ablation.

---

1. CBA Group
2. Chemo-Naive group
3. Chemo-treated lesions
4. Chemo-naïve lesions
5. Lesion size at time of diagnosis
6. Lesion size at time of ablation
7. ΔS_{DIA-ABL}
8. V_{DIA-ABL}
9. SIR classification
10. CIEMAR
11. COLLISION trial
12. RFA
13. ESMO
14. MWA
15. CLM
16. SIR
17. ΔS
18. V
19. ABL
20. CBA
21. Chemo-Naive
22. Chemo-treated
23. Literature
24. Published data
25. Published cohorts
26. Literature reports
27. MWA technologies
28. Biliary ducts injuries
29. Non-inferiority
30. Multivariate analysis
31. Clinical practice
32. European prospective registry
33. Phase III trial
34. Single-center cohort
35. SIR classification
36. Lesion size
37. Margin width
38. LTPFS
the edges of the ablation scar with a minimum distance of 1 cm. Although intra-segment progression cannot be used as a predictor (obviously it was observed during follow-up), the relationship with LTP focuses the attention at the local level rather than at a systemic level, highlighting the possibility of a correlation between LTP and a locally aggressive behavior of the tumor. Although we could not demonstrate in this series an independent role of RAS mutational status as demonstrated in other series [30–32], this finding concerning the intra-segment recurrence is in line with surgical literature and histopathological research that identifies and describes different local histopathological growth patterns [33] even on molecular basis [34]. Overall, from the interventional perspective, these data stress the importance of adequate minimum margins of ablations, at least of 5 mm according to our data (and consistently with the literature [22]).

Lesion size was found as an independent predictor both at time of diagnosis and at time of ablation. Furthermore, \( \Delta S_{DA-AB} \) and \( V_{DA-AB} \) were not found to be predictors of different LTPFS. Although \( V_{DA-AB} \) tended to be higher in
the group without chemotherapy, CBA was not found as an independent predictor for LTPFS; chemotherapy did slightly reduce the kinetic growth of the lesion. However, mean lesion sizes at ablation and at time of diagnosis (in both subgroups) were under 2 cm and therefore clearly amenable to ablative treatments. We did not find any statistical difference between size in chemo-treated CLM at diagnosis and size in chemo-naïve CLM at ablation.

Even though statistical significance was not achieved, higher LTP rates were observed in the CBA group compared to the chemo-naïve group (32.1 vs 23.9%). Furthermore, ablation margins were statistically worse in the CBA group compared to the chemo-naïve group despite similar amount of delivered energy and ablation sites. This finding can be related with the changes in liver parenchyma texture and enhancement during chemotherapy, with subsequent difficulties in targeting the index lesions during the procedure [35–37].

To date, therapeutic decision-making regarding the use of thermal ablation is mostly left to multidisciplinary tumor board consultations and local expertise. Our data provide new insights on the interaction between chemotherapy and T-MWA [6]. According to the phase II CLOCC trial [38] as well as a metanalysis by Meijerink et al. [39], there is a synergistic effect between systemic and local therapies that improve long-term overall survival; in the CLOCC trial, thermal ablation was performed upfront in the RFA plus chemotherapy group and only 6 patients had previously received a chemotherapeutic regimen.

Few and inconclusive data [40] exist in literature concerning the oncological management of CLM prior to local treatment and in particular prior to ablation. Benhaim et al. [8] demonstrated that RFA, for CLM initially greater than 25 mm, but downsized by neo-adjuvant chemotherapy, is associated with increased rate of LTP. Indeed, the persistence of microscopic residual disease, not visible at the radiological evaluation, following CBA may lead to some difficulties in the correct planning of ablative margins (a concept similar to that of missing metastases [41]). Accordingly, our data did not find a significant role of CBA on LTPFS with LTP rates slightly superior in those who received CBA; furthermore, adequate ablation margins were more frequently observed in the chemo-naïve group. Lastly, lesion size was an independent factor already at time of diagnosis.

Taken together, our data underline the potential role of treating CLM in a short timeframe following diagnosis and suggest thermal ablation upfront with respect to chemotherapy. Although many questions remain open and evidence should be more robust, in consideration of these findings and those already present in the literature [8, 8–40], we believe that ablation upfront to chemotherapy should be a concept to be highly considered by interventional radiologists and carefully evaluated during tumor board evaluations, by introducing the ASARA principle: to deliver ablative treatments for CLM As Soon As Reasonably Achievable.

Our paper has some limitations. First of all, the follow-up time is relatively short if compared with other papers [9, 24, 27] on CLM ablation. However, the Thermosphere™...
technology was launched at the end of 2014, and in general, MWA is a younger technology compared to RFA. Although 19 months of mean follow-up may not appear very long, the CIEMAR registry (endorsed by CIRSE, on the same technology and disease) has its primary endpoint (local tumor control) at 12 months after treatment.

In patients receiving chemotherapy prior to ablation, regimens were those indicated by ESMO/NCCN guidelines [5, 6], in particular according to the molecular profiles of the diseases (doublet or triplet regimens plus bevacizumab or anti-EGFR agents). This does not make this treatment subgroup uniform but it correctly reflects current practice and patient management.

Differently from other series, we did not find any statistical significance by Ras mutational status. This result may be affected by data incompleteness related to the retrospective nature of this study.

Lastly, in our study cohort, lesion site was not classified as peri-hilar or not, and this may generate a bias when assessing biliary complications.

In conclusion, T-MWA seems an effective and safe technology for CLM treatment, with no biliary complications. LTPFS is linked to intra-segment recurrence, highlighting the potential relationship with the tumor biology and its local aggressiveness. Care should be exercised in choosing the correct timing of the ablation: anticipating ablation As Soon As Reasonably Achievable (ASARA) may allow proper planning of ablation margins without losing the potential benefits of post-ablation chemotherapy.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00330-021-08497-2.

**Funding** The authors state that this work has not received any funding.

**Declarations**

**Guarantor** The scientific guarantor of this publication is Marco Calandri.

**Conflict of interest** The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

**Statistics and biometry** One of the authors (R.S.) has significant statistical expertise.

**Informed consent** Written informed consent was waived by the Institutional Review Board.

**Ethical approval** Institutional Review Board approval was obtained.

**Methodology**
- Retrospective
- Observational
- Multicentre study

---

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Leporrier J, Maurel J, Chiche L et al (2006) A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg 93:465–474. https://doi.org/10.1002/bjs.5278
2. Manfredi S, Lepage C, Hatem C, Coatmeur O, Favier J, Bouvier AM (2006) Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244:254–259. https://doi.org/10.1097/01.sla.0000217629.94941.cf
3. Khattak MA, Martin HL, Beeke C et al (2012) Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer. Clin Colorectal Cancer 11:247–254. https://doi.org/10.1016/j.clcco.2012.06.004
4. Engstrand J, Nilsson H, Strömberg C, Jonas E, Freedman J (2018) Colorectal cancer liver metastases - a population-based study on incidence, management and survival. BMC Cancer 18.https://doi.org/10.1186/s12885-017-3925-x
5. Benson AB, Venook AP, Al-Hawary MM et al (2018) NCCN Guidelines ® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines. J Natl Compr Cancer Netw 16:359–369. https://doi.org/10.6004/jnccn.2018.0021
6. Van Cutsen E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386–1422. https://doi.org/10.1093/annonc/mdw235
7. Fonck M, Perez JT, Catena V et al (2018) Pulmonary thermal ablation enables long chemotherapy-free survival in metastatic colorectal cancer patients. Cardiovasc Intervent Radiol 41:1727–1734. https://doi.org/10.1007/s00270-018-1939-7
8. Benhaim L, El Hajjami M, Malafosse R et al (2018) Radiofrequency ablation for colorectal cancer liver metastases initially greater than 25 mm but downsized by neo-adjuvant chemotherapy is associated with increased rate of local tumor progression. HPB (Oxford) 20:76–82. https://doi.org/10.1016/j.hpb.2017.08.023
9. Han K, Kim JH, Yang SG et al (2020) A single-center retrospective analysis of periprocedural variables affecting local tumor progression after radiofrequency ablation of colorectal cancer liver metastases. Radiology 298:212–218. https://doi.org/10.1148/RADIOL.2020200109
10. Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–321. https://doi.org/10.1097/00000658-199909000-00004
11. Ahmed M (2014) Image-guided tumor ablation: standardization of terminology and reporting Criteria-A 10-year update. Radiology 273:241–260. https://doi.org/10.1148/radiol.14132958
12. Sacks D, McClenney TE, Cardella JF, Lewis CA (2003) Society of Interventional Radiology clinical practice guidelines. J Vasc
13. Crocetti L, De Baere T, Lencioni R (2010) Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol 33:11–17. https://doi.org/10.1007/s00270-009-9736-y

14. Wang X, Sofocleous CT, Erinjeri JP et al (2013) Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol 36:166–175. https://doi.org/10.1007/s00270-012-0377-1

15. Puijk RS, Ruarus AH, Vroomen LGPH et al (2018) Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial. BMC Cancer 18. https://doi.org/10.1186/s12885-018-4716-8

16. Shady W, Petre EN, Gonen M et al (2016) Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes - a 10-year experience at a single center. Radiology 278:601–611. https://doi.org/10.1148/radiol.2015142489

17. Liang P, Wang Y, Yu XL, Dong B (2009) Malignant liver tumors: treatment with percutaneous microwave ablation - complications among cohort of 1136 patients. Radiology 251:933–940. https://doi.org/10.1148/radiol.2513081740

18. van Tilborg AAJM, Scheffler HJ, de Jong MC et al (2016) MWA versus RFA for perivascular and peribiliary CRLM: a retrospective patient- and lesion-based analysis of two historical cohorts. Cardiovasc Intervent Radiol 39:1438–1446. https://doi.org/10.1007/s00270-016-1413-3

19. Solibiati L, Ahmed M, Cova L et al (2012) Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 265:958–968. https://doi.org/10.1148/radiol.12111851

20. Yang G, Wang G, Sun J et al (2021) The prognosis of radiofrequency ablation versus hepatic resection for patients with colorectal liver metastases: a systematic review and meta-analysis based on 22 studies. Int J Surg 87. https://doi.org/10.1016/j.ijsu.2021.105896

21. Sofocleous CT, Petre EN, Gonen M et al (2011) CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy. J Vasc Interv Radiol 22:755–761. https://doi.org/10.1016/j.jvir.2011.01.451

22. Velti A, Saccheto P, Tosetti I et al (2008) Radiofrequency ablation of colorectal liver metastases: small size favorably predicts technical effectiveness and survival. Cardiovasc Intervent Radiol 31:948–956. https://doi.org/10.1007/s00270-008-9362-0

23. Calandrini M, Gazzerra C, Giurazza F et al (2020) Oligometastatic colorectal cancer management: a survey of the Italian College of Interventional Radiology. Cardiovasc Intervent Radiol 43:1474–1483. https://doi.org/10.1007/s00270-020-02516-3

24. Alonzo M, Bos A, Bennett S, Ferral H (2015) The EmprintTM Ablation System with ThermosphereTM Technology: one of the newer next-generation microwave ablation technologies. Semin Intervent Radiol 32:335–338. https://doi.org/10.1055/s-0035-1564811

25. De Cobelli F, Marra P, Ratti F et al (2017) Microwave ablation of liver malignancies: comparison of effects and early outcomes of percutaneous and intraoperative approaches with different liver conditions: new advances in interventional oncology: state of the art. Med Oncol 34. https://doi.org/10.1007/s12032-017-0903-8

26. Vogl TJ, Bastian LM, Nour-Eldin NEA et al (2018) Evaluation of microwave ablation of liver malignancy with enabled constant spatial energy control to achieve a predictable spherical ablation zone. Int J Hyperth 34:492–500. https://doi.org/10.1080/02656736.2017.1358408

27. Takahashi H, Kahramangil B, Berber E (2018) Local recurrence after microwave thermosphere ablation of malignant liver tumors: results of a surgical series. Surgery 163:709–713. https://doi.org/10.1016/j.surg.2017.10.026

28. Soulen MC, Sofocleous CT (2021) Achieving curative ablation outcomes: it is all about the imaging. Radiology 298:219–220. https://doi.org/10.1148/RADIOL.2020203930

29. Gillams A, Goldberg N, Ahmed M et al (2015) Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontieres meeting 2013. Eur Radiol 25:3438–3454. https://doi.org/10.1007/s00330-015-3779-z

30. Calandrini M, Yamashita S, Gazzerra C et al (2018) Ablation of colorectal liver metastasis: interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival. Eur Radiol 28:2727–2734. https://doi.org/10.1007/s00330-017-5273-2

31. Shady W, Petre EN, Vakiani E et al (2017) Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. Oncotarget 8:66117–66127. https://doi.org/10.18632/oncotarget.19806

32. Odisio BC, Yamashita S, Huang SY et al (2017) Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. Br J Surg 104:760–768. https://doi.org/10.1002/bjs.10490

33. Van Dam PJ, Van Der Stok EP, Teuwen LA et al (2017) International consensus guidelines for scoring the histopathological growth patterns of liver metastasis. Br J Cancer 117:1427–1441. https://doi.org/10.1038/bjc.2017.334

34. Brudvik KW, Mise Y, Chung MH et al (2016) RAS mutation predicts positive resection margins and narrower resection margins in patients undergoing resection of colorectal liver metastases. Ann Surg Oncol 23:2635–2643. https://doi.org/10.1245/s10434-016-1817-2

35. Beckers RCJ, Lamberts DMI, Lahaye MJ et al (2018) Advanced imaging to predict response to chemotherapy in colorectal liver metastases – a systematic review. HPB (Oxford) 20:120–127. https://doi.org/10.1016/j.hpb.2017.10.013

36. Van Kessel CS, Buckens CPM, Van Den Bosch MAAJ et al (2012) Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol 19:2805–2813. https://doi.org/10.1245/s10434-012-2300-z

37. Zamboni GA, Mazzaro A, Mansueto G (2020) How to best image colorectal liver metastases. Curr Colorectal Cancer Rep 16:1–17. https://doi.org/10.1007/s10434-019-00447-x

38. Ruijs T, Van Coevorden F, Punt CJA et al (2017) Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst 109. https://doi.org/10.1093/jnci/djx015

39. Meijerink MR, Puijk RS, van Tilborg AAJM et al (2018) Radiofrequency and microwave ablation compared to systemic chemotherapy and to partial hepatectomy in the treatment of colorectal liver metastases: a systematic review and meta-analysis. Cardiovasc Intervent Radiol 41:1189–1204. https://doi.org/10.1007/s00270-018-1959-3

40. Dijkstra M, Nieuwenhuizen S, Puijk RS et al (2021) The role of neoadjuvant chemotherapy in repeat local treatment of recurrent colorectal liver metastases: a systematic review and meta-analysis. Cancers (Basel) 13:1–20. https://doi.org/10.3390/cancers13030378

41. Kuhlmann K, van Hilst J, Fisher S, Poston G (2016) Management of disappearing colorectal liver metastases. Eur J Surg Oncol 42:1798–1805. https://doi.org/10.1016/j.ejso.2016.05.005